In the following weeks, McKinsey rolled out ever-stronger recommendations to keep the OxyContin pipeline flowing, such as targeting the heaviest prescribers, sharply increasing prescriber visits by sales reps, using patient advocacy groups to push back against efforts to limit “appropriate” access, accelerating efforts to set up an alternative drug distribution channel, and engaging in high-level talks with Walgreens.
